Interaction of [(VO)-O-IV(acac)(2)] with Human Serum Transferrin and Albumin
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.1/13033 |
Resumo: | VO(acac)(2)] is a remarkable vanadium compound and has potential as a therapeutic drug. It is important to clarify how it is transported in blood, but the reports addressing its binding to serum proteins have been contradictory. We use several spectroscopic and mass spectrometric techniques (ESI and MALDI-TOF), small-angle X-ray scattering and size exclusion chromatography (SEC) to characterize solutions containing [VO(acac)(2)] and either human serum apotransferrin (apoHTF) or albumin (HSA). DFT and modeling protein calculations are carried out to disclose the type of binding to apoHTF. The measured circular dichroism spectra, SEC and MALDI-TOF data clearly prove that at least two VOacac moieties may bind to apoHTF, most probably forming [(VO)-O-IV(acac)(apoHTF)] complexes with residues of the HTF binding sites. No indication of binding of [VO(acac)(2)] to HSA is obtained. We conclude that (VO)-O-IV-acac species may be transported in blood by transferrin. At very low complex concentrations speciation calculations suggest that [(VO)(apoHTF)] species form. |
id |
RCAP_5c0d2635aa422c60f1664a9f03e94062 |
---|---|
oai_identifier_str |
oai:sapientia.ualg.pt:10400.1/13033 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Interaction of [(VO)-O-IV(acac)(2)] with Human Serum Transferrin and AlbuminHeteroleptic oxidovanadium(Iv) compoundsAntidiabetic vanadium complexesNuclear double-resonanceRay solution scatteringRed-blood-cellsCrystal-structureOxovanadium(Iv) complexesN-lobeTyrosine phosphorylationCoordination chemistryVO(acac)(2)] is a remarkable vanadium compound and has potential as a therapeutic drug. It is important to clarify how it is transported in blood, but the reports addressing its binding to serum proteins have been contradictory. We use several spectroscopic and mass spectrometric techniques (ESI and MALDI-TOF), small-angle X-ray scattering and size exclusion chromatography (SEC) to characterize solutions containing [VO(acac)(2)] and either human serum apotransferrin (apoHTF) or albumin (HSA). DFT and modeling protein calculations are carried out to disclose the type of binding to apoHTF. The measured circular dichroism spectra, SEC and MALDI-TOF data clearly prove that at least two VOacac moieties may bind to apoHTF, most probably forming [(VO)-O-IV(acac)(apoHTF)] complexes with residues of the HTF binding sites. No indication of binding of [VO(acac)(2)] to HSA is obtained. We conclude that (VO)-O-IV-acac species may be transported in blood by transferrin. At very low complex concentrations speciation calculations suggest that [(VO)(apoHTF)] species form.Fundacao para a Ciencia e Tecnologia (FCT), Portugal [ RECI/QEQMED/0330/2012, PTDC/QEQ-MED/1902/2014]FCT [IF/00100/2013, IF/00007/2015]PROTEOMASS Scientific SocietyUCIBIO, Unidade de Ciencias Biomoleculares Aplicadas [UID/Multi/04378/2013]ERDF [POCI-01-0145-FEDER-007728, POCI-01-0145-FEDER-007265]WileySapientiaCorreia, IsabelChorna, IelyzavetaCavaco, IsabelRoy, SomnathKuznetsov, Maxim L.Ribeiro, NadiaJustino, GoncaloMarques, FernandaSantos-Silva, TeresaSantos, Marino F. A.Hugo, M. Santos E.Capelo, Jose L.Doutch, JamesPessoa, Joao Costa2019-11-20T15:07:25Z2017-082017-08-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.1/13033eng1861-472810.1002/asia.201700469info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-24T10:25:03Zoai:sapientia.ualg.pt:10400.1/13033Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:04:15.164510Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Interaction of [(VO)-O-IV(acac)(2)] with Human Serum Transferrin and Albumin |
title |
Interaction of [(VO)-O-IV(acac)(2)] with Human Serum Transferrin and Albumin |
spellingShingle |
Interaction of [(VO)-O-IV(acac)(2)] with Human Serum Transferrin and Albumin Correia, Isabel Heteroleptic oxidovanadium(Iv) compounds Antidiabetic vanadium complexes Nuclear double-resonance Ray solution scattering Red-blood-cells Crystal-structure Oxovanadium(Iv) complexes N-lobe Tyrosine phosphorylation Coordination chemistry |
title_short |
Interaction of [(VO)-O-IV(acac)(2)] with Human Serum Transferrin and Albumin |
title_full |
Interaction of [(VO)-O-IV(acac)(2)] with Human Serum Transferrin and Albumin |
title_fullStr |
Interaction of [(VO)-O-IV(acac)(2)] with Human Serum Transferrin and Albumin |
title_full_unstemmed |
Interaction of [(VO)-O-IV(acac)(2)] with Human Serum Transferrin and Albumin |
title_sort |
Interaction of [(VO)-O-IV(acac)(2)] with Human Serum Transferrin and Albumin |
author |
Correia, Isabel |
author_facet |
Correia, Isabel Chorna, Ielyzaveta Cavaco, Isabel Roy, Somnath Kuznetsov, Maxim L. Ribeiro, Nadia Justino, Goncalo Marques, Fernanda Santos-Silva, Teresa Santos, Marino F. A. Hugo, M. Santos E. Capelo, Jose L. Doutch, James Pessoa, Joao Costa |
author_role |
author |
author2 |
Chorna, Ielyzaveta Cavaco, Isabel Roy, Somnath Kuznetsov, Maxim L. Ribeiro, Nadia Justino, Goncalo Marques, Fernanda Santos-Silva, Teresa Santos, Marino F. A. Hugo, M. Santos E. Capelo, Jose L. Doutch, James Pessoa, Joao Costa |
author2_role |
author author author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
Sapientia |
dc.contributor.author.fl_str_mv |
Correia, Isabel Chorna, Ielyzaveta Cavaco, Isabel Roy, Somnath Kuznetsov, Maxim L. Ribeiro, Nadia Justino, Goncalo Marques, Fernanda Santos-Silva, Teresa Santos, Marino F. A. Hugo, M. Santos E. Capelo, Jose L. Doutch, James Pessoa, Joao Costa |
dc.subject.por.fl_str_mv |
Heteroleptic oxidovanadium(Iv) compounds Antidiabetic vanadium complexes Nuclear double-resonance Ray solution scattering Red-blood-cells Crystal-structure Oxovanadium(Iv) complexes N-lobe Tyrosine phosphorylation Coordination chemistry |
topic |
Heteroleptic oxidovanadium(Iv) compounds Antidiabetic vanadium complexes Nuclear double-resonance Ray solution scattering Red-blood-cells Crystal-structure Oxovanadium(Iv) complexes N-lobe Tyrosine phosphorylation Coordination chemistry |
description |
VO(acac)(2)] is a remarkable vanadium compound and has potential as a therapeutic drug. It is important to clarify how it is transported in blood, but the reports addressing its binding to serum proteins have been contradictory. We use several spectroscopic and mass spectrometric techniques (ESI and MALDI-TOF), small-angle X-ray scattering and size exclusion chromatography (SEC) to characterize solutions containing [VO(acac)(2)] and either human serum apotransferrin (apoHTF) or albumin (HSA). DFT and modeling protein calculations are carried out to disclose the type of binding to apoHTF. The measured circular dichroism spectra, SEC and MALDI-TOF data clearly prove that at least two VOacac moieties may bind to apoHTF, most probably forming [(VO)-O-IV(acac)(apoHTF)] complexes with residues of the HTF binding sites. No indication of binding of [VO(acac)(2)] to HSA is obtained. We conclude that (VO)-O-IV-acac species may be transported in blood by transferrin. At very low complex concentrations speciation calculations suggest that [(VO)(apoHTF)] species form. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017-08 2017-08-01T00:00:00Z 2019-11-20T15:07:25Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.1/13033 |
url |
http://hdl.handle.net/10400.1/13033 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
1861-4728 10.1002/asia.201700469 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Wiley |
publisher.none.fl_str_mv |
Wiley |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799133278315216896 |